Canada - English - Health Canada

mylan pharmaceuticals ulc - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

astrazeneca canada inc - olaparib - tablet - 100mg - olaparib 100mg - antineoplastic agents

Canada - English - Health Canada

astrazeneca canada inc - olaparib - tablet - 150mg - olaparib 150mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - olaparib 100mg;   - film coated tablet - 100 mg - active: olaparib 100mg   excipient: colloidal silicon dioxide copovidone hypromellose iron oxide yellow macrogol 400 mannitol purified water sodium stearyl fumarate titanium dioxide - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens. lynparza is indicated as monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced brca-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either: - a deleterious or suspected deleterious brca mutation (germline or somatic), and/or - genomic instability hrd status should be determined by an experienced laboratory using a validated test method.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - olaparib 150mg;   - film coated tablet - 150 mg - active: olaparib 150mg   excipient: colloidal silicon dioxide copovidone hypromellose iron oxide black iron oxide yellow macrogol 400 mannitol purified water sodium stearyl fumarate titanium dioxide - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens. lynparza is indicated as monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced brca-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either: - a deleterious or suspected deleterious brca mutation (germline or somatic), and/or - genomic instability hrd status should be determined by an experienced laboratory using a validated test method.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - buserelin acetate -

Israel - English - Ministry of Health

j-c health care ltd - apalutamide - film coated tablets - apalutamide 60 mg - apalutamide - "erleada is indicated in adult men for the treatment of• metastatic hormone‐sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt)• non-metastatic castration-resistant prostate cancer (nm-crpc)."

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - olaparib - tablet, film coated - olaparib 100mg

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - olaparib - tablet, film coated - olaparib 150mg

Singapore - English - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - enzalutamide - capsule, liquid filled - enzalutamide 40.0 mg